Comparing the current results to its competitors, Ascendis Pharma A reported Revenue increase in the 4 quarter 2025 by 98.03 % year on year. The sales growth was above Ascendis Pharma A's competitors' average revenue growth of 86.21 %, achieved in the same quarter.
Ascendis Pharma A's Comment on Competition and Industry Peers
The pharmaceutical industry is characterized by intense competition and rapid change. Competitors include multinational pharmaceutical companies, established biotechnology firms, specialty pharmaceutical and generic drug companies, universities, and research institutions. Many of these competitors possess greater resources, larger research and development capabilities, and more experienced marketing and manufacturing teams, which can facilitate faster regulatory approvals and more effective product marketing. Smaller or early-stage companies may also pose competition, particularly through partnerships with larger established firms. Competitors may develop or acquire advanced technologies and drug products that could make existing products obsolete or less competitive. Additionally, many competitors have extensive experience in conducting preclinical and clinical trials and securing regulatory approvals. Named competitors include Bachem, Eyconis, Inc, Frazier, Frazier Life Sciences, HealthQuest Capital, RA Capital Management, venBio, and VISEN.
July 7, 2025
Uncovering Ascendis Pharma s Promising Data Presentations and Revenue Boom Ahead of ENDO 2025 In a significant development for Ascendis Pharma A/S (Nasdaq: ASND), the company recently announced a lineup of pivotal oral presentations set for ENDO 2025, the annual meeting of the Endocrine Society. Scheduled to take place from July 12-15, 2025, in San Francisco, the conference serves as a platform for highlighting groundbreaking research and innovation in endocrinology. Ascendis is preparing to make a notable impact with presentations detailing their recent advancements in rare disease treatments. Key Presentations at ENDO 2025 Dr. Aliya Khan will unveil new data from Week 156 of the company s Phase 3 PaTHway T...
June 3, 2024
Ascendis Pharma Presents New Data on Promising Treatments at ASCO 2024Ascendis Pharma, a biopharmaceutical company based in Denmark, has recently presented new data and updated results from its clinical trials at the American Society of Clinical Oncology (ASCO) 2024 conference. The findings highlight the efficacy and safety of their innovative treatment approaches.In the initial cohort of patients with anti-PD-1 refractory melanoma, Ascendis Pharma conducted a Phase 1/2 clinical trial evaluating the combination of TransCon IL-2 and TransCon TLR7/8 Agonist. The trial showed that 40% of efficacy-evaluable patients (2 out of 5) exhibited confirmed clinical responses. Importantly, no new safety signals were obse...
May 13, 2024
Improving Renal Function in Adults with Chronic Hypoparathyroidism: TransCon PTH Shows Promising Results According to Ascendis Pharma s Phase 3 PaTHway TrialCOPENHAGEN, Denmark, May 13, 2024 - Ascendis Pharma A/S (Nasdaq: ASND) recently revealed their two-year findings from a post-hoc analysis conducted on their Phase 3 PaTHway trial. This analysis demonstrates significant and sustained improvements in renal function for adults suffering from chronic hypoparathyroidism who were treated with TransCon PTH (palopegteriparatide). The data was presented during the European Congress of Endocrinology 2024 (ECE 2024) by Professor Peter Schwarz, M.D., from the University of Copenhagen. These groundbreaking results ha...
Recently, groundbreaking results from the Phase 3 foresiGHt trial have shed light on the incredible potential of TransCon hGH (lonapegsomatropin), an innovative treatment for adults suffering from growth hormone deficiency. As the world grapples with the challenges of hormonal imbalances, TransCon hGH has emerged as a beacon of hope, soaring above the competition and delivering statistically superior outcomes when compared to placebo. Unveiling Promising Efficacy Results: In the quest to address growth hormone deficiency, TransCon hGH has proven itself to be a game-changer. The trial s primary efficacy and key secondary endpoints have demonstrated a significant reduction in trunk fat and a ...
November 29, 2023
Ascendis Pharma Announces Strategic Partnership with Teijin Limited in Japan: Teijin to Lead Development and Commercialization of TransCon Therapies In a major strategic move, Ascendis Pharma has joined forces with Teijin Limited to develop and bring innovative therapies to patients in Japan. As part of this partnership, Teijin will receive an exclusive license to further develop and commercialize Ascendis Pharma s groundbreaking TransCon hGH, TransCon PTH, and TransCon CNP in the Japanese market. TransCon hGH, TransCon PTH, and TransCon CNP are three novel therapies that have shown immense potential in treating hormone deficiency disorders. TransCon hGH is designed to provide a sustained release of ...
Aditxt Inc operates on a business model that focuses on developing and commercializing technologies used in the field of biotechnology and personalized medicine. They leverage their expertise in genomics and diagnostics to offer innovative solutions that enable individuals to better understand and manage their health. Through their products and services, Aditxt aims to deliver personalized diagnostics and immune monitoring platforms to empower people in making informed decisions about their well-being.
Ensysce Biosciences Inc is a biopharmaceutical company that operates on a business model centered around developing and commercializing novel therapies using their proprietary drug delivery technology, known as MedXPRESS™. This technology allows for precise control of drug release and enhanced delivery to target tissues, with a focus on improving therapeutic outcomes and patient compliance.
Galectin Therapeutics Inc is a biotechnology company that focuses on developing therapies for fibrotic diseases and cancer by targeting galectin proteins. Their business model involves conducting research and development to create novel galectin-targeting drugs, partnering with pharmaceutical companies for joint development and commercialization, and potentially seeking regulatory approval for their products to enter the market. They generate revenue through licensing agreements, collaborations, and potential sales of their developed therapies.
Werewolf Therapeutics Inc operates with a business model focused on utilizing innovative technologies to develop therapies targeting cancer using immune cell activation.
Sources:
Ascendis Pharma A’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Ascendis Pharma A versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
